TNSN04169A1 - Composes oxo-azabicycliques - Google Patents

Composes oxo-azabicycliques

Info

Publication number
TNSN04169A1
TNSN04169A1 TNP2004000169A TNSN04169A TNSN04169A1 TN SN04169 A1 TNSN04169 A1 TN SN04169A1 TN P2004000169 A TNP2004000169 A TN P2004000169A TN SN04169 A TNSN04169 A TN SN04169A TN SN04169 A1 TNSN04169 A1 TN SN04169A1
Authority
TN
Tunisia
Prior art keywords
group
atom
description
inclusive
integer
Prior art date
Application number
TNP2004000169A
Other languages
English (en)
Inventor
Henry Jacobelli
Catherine Kostlan
Jack Li
Wen-Song Yue
Bernard Gaudilliere
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of TNSN04169A1 publication Critical patent/TNSN04169A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un composé choisi parmi ceux de formule (I) Dans laquelle : X1; X2 et X3 représentent des atomes de N ou des groupes –CR3 dans lesquels R3 est tel que défini dans la description; G1 représente un groupe choisi parmi ceux de formules (i/a) et (i/b) dans lesquelles R4; R5 et R6 sont tels que définis dans la description; G2 représente un groupe choisi entre un triple liaison carbone-carbone; un groupe –CH=C=CH-; un groupe C=O; groupe C=S; un groupe S(O)n; dans lequel n1 représente un nombre entier de 0 à 2 inclus; ou un groupe de formule (i/c) dans laquelle Y1 représente un atome de 0; un atome de S; un groupe –NH ou un groupe –N-alkyle; et Y2 représente un atome de 0; un atome de S; un groupe –NH; ou un groupe –N alkyle; n représente un nombre entier de 0 à 6 inclus et m représente un nombre entier de 0 à 7 inclus; Z1 représente un groupe – CR9 R10; dans lequel R9 et R10 sont tels que définis dans la description; A représente un système cyclique; R1 représente un groupe choisi entre H; des groupes alkyle; alcényle et alcynyle facultativement substitués et le groupe de formule (i/d) dans laquelle p; Z2; B; q et G3 sont tels que définis dans la description et; facultativement; ses isomères optiques; son N-oxyde et ses sels d'addition formés avec un acide ou une base pharmaceutiquement acceptable; et des produits médicamenteux le contenant sont utiles comme inhibiteurs spécifiques de la métalloprotéase de matrice de type 13.
TNP2004000169A 2002-03-08 2004-09-03 Composes oxo-azabicycliques TNSN04169A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (fr) 2002-03-08 2002-03-08 Composes oxo azabicycliques
PCT/EP2003/002277 WO2003076417A2 (fr) 2002-03-08 2003-03-06 Composes oxo-azabicycliques

Publications (1)

Publication Number Publication Date
TNSN04169A1 true TNSN04169A1 (fr) 2007-03-12

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000169A TNSN04169A1 (fr) 2002-03-08 2004-09-03 Composes oxo-azabicycliques

Country Status (25)

Country Link
EP (1) EP1492775A2 (fr)
JP (1) JP2005526070A (fr)
KR (1) KR20040095270A (fr)
CN (1) CN1738806A (fr)
AP (1) AP2004003125A0 (fr)
AR (1) AR039562A1 (fr)
AU (2) AU2002249275A1 (fr)
BR (1) BR0308280A (fr)
CA (1) CA2478706A1 (fr)
CO (1) CO5601020A2 (fr)
EA (1) EA200401053A1 (fr)
EC (1) ECSP045278A (fr)
IL (1) IL163818A0 (fr)
IS (1) IS7414A (fr)
MA (1) MA27183A1 (fr)
MX (1) MXPA04008681A (fr)
NO (1) NO20044041L (fr)
OA (1) OA12782A (fr)
PA (1) PA8568501A1 (fr)
PE (1) PE20031018A1 (fr)
PL (1) PL372622A1 (fr)
SV (1) SV2003001495A (fr)
TN (1) TNSN04169A1 (fr)
UY (1) UY27700A1 (fr)
WO (2) WO2003076416A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2004014892A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
EP1553949B1 (fr) 2002-08-13 2007-04-18 Warner-Lambert Company LLC Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle
WO2004014378A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloprotease bicycliques condenses
WO2005016926A1 (fr) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Derives de pyrido[3,4-d]pyrimidine utiles comme inhibiteurs de la metalloproteinase-13 de matrice
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0510305A (pt) * 2004-04-30 2007-10-02 Takeda Pharmaceutical composto ou um sal do mesmo, pródroga ou um sal da mesma, agente farmacêutico, método de produção do composto ou um sal do mesmo, inibidor de metaloproteinase de matriz ou um sal do mesmo ou uma pródroga do mesmo, método de inibir uma metaloproteinase de matriz, e, uso de um composto ou de um sal do mesmo ou de uma pródroga do mesmo
JP2008502666A (ja) * 2004-06-15 2008-01-31 アストラゼネカ アクチボラグ 抗癌剤としての置換キナゾロン類
CA2665476A1 (fr) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Composes heterocycliques azotes bicycliques pour une utilisation en tant qu'inhibiteurs de stearoyl-coa-desaturase
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE057090T2 (hu) 2015-09-23 2022-04-28 Janssen Pharmaceutica Nv BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5380398A (en) * 1996-12-17 1998-07-15 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz

Also Published As

Publication number Publication date
CO5601020A2 (es) 2006-01-31
AU2002249275A1 (en) 2003-09-22
WO2003076417A2 (fr) 2003-09-18
CA2478706A1 (fr) 2003-09-18
WO2003076417A3 (fr) 2003-11-13
PL372622A1 (en) 2005-07-25
MXPA04008681A (es) 2004-12-06
JP2005526070A (ja) 2005-09-02
IL163818A0 (en) 2005-12-18
AR039562A1 (es) 2005-02-23
EA200401053A1 (ru) 2005-04-28
SV2003001495A (es) 2003-11-04
BR0308280A (pt) 2004-12-28
OA12782A (en) 2006-07-10
MA27183A1 (fr) 2005-01-03
PE20031018A1 (es) 2004-01-09
EP1492775A2 (fr) 2005-01-05
NO20044041L (no) 2004-10-07
AP2004003125A0 (en) 2004-09-30
AU2003212307A1 (en) 2003-09-22
WO2003076416A1 (fr) 2003-09-18
UY27700A1 (es) 2003-10-31
PA8568501A1 (es) 2003-12-19
IS7414A (is) 2004-08-19
ECSP045278A (es) 2004-10-26
CN1738806A (zh) 2006-02-22
KR20040095270A (ko) 2004-11-12

Similar Documents

Publication Publication Date Title
TNSN04169A1 (fr) Composes oxo-azabicycliques
HUP0203700A2 (hu) N-szubsztituált cianopirrolidinek és cukorbetegség-ellenes szerként való alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
CA2481461A1 (fr) Derives de n-[phenyl(piperidin-2-yl) methyl] benzamide, leur preparation et leur application en therapeutique
MA30014B1 (fr) Derives spirocycliques
LU90011I2 (fr) Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EP0343900A3 (fr) Composés pipéraziniques
MA30695B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole -2-carboxamides, leur preparation et leur application en therapeutique.
TNSN05172A1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
MA28742B1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
MA27197A1 (fr) Sels de tolterodine
MA27712A1 (fr) Triazoles utiles en therapeutique
MA27492A1 (fr) Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
EP0262053A3 (fr) Nouveaux dérivés d'amino-acides, leur procédé de préparation et compositions pharmaceutiques les contenant
MA27260A1 (fr) Nouveaux dérivés de 3-(4-oxo-4H-chromén-2-yl)-(1H)-quinoléine-4-ones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
FR2854634A1 (fr) Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2859208B1 (fr) Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2308780A1 (fr) Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TNSN08237A1 (fr) Derives spirocycliques
MA27947A1 (fr) Pyrimidines 2-substituees
MA27545A1 (fr) Nouveaux dérivés de benzothiadiazines fluorées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CA2364199A1 (fr) Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent